Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations
AuthorsWatson, Karriem S.
Blok, Amanda C.
Simon, Melissa A.
Studts, Jamie L.
Lillie, Sarah E.
Ostroff, Jamie S.
Winn, Robert A.
Document TypeJournal Article
Behavior and Behavior Mechanisms
Translational Medical Research
MetadataShow full item record
AbstractThe Society of Behavioral Medicine (SBM) supports the United States Preventive Services Task Force (USPSTF) recommendation of low-dose computed tomography (LDCT) screening of the chest for eligible populations to reduce lung cancer mortality. Consistent with efforts to translate research findings into real-world settings, SBM encourages health-care providers and health-care systems to (1) integrate evidence-based tobacco treatment as an essential component of LDCT-based lung cancer screening, (2) examine the structural barriers that may impact screening uptake, and (3) incorporate shared decision-making as a clinical platform to facilitate consultations and engagement with individuals at high risk for lung cancer about the potential benefits and harms associated with participation in a lung cancer screening program. We advise policy makers and legislators to support screening in high-risk populations by continuing to (1) expand access to high quality LDCT-based screening among underserved high-risk populations, (2) enhance cost-effectiveness by integrating evidence-based tobacco treatments into screening in high-risk populations, and (3) increase funding for research that explores implementation science and increased public awareness and access of diverse populations to participate in clinical and translational research.
SourceTransl Behav Med. 2016 Dec;6(4):669-671. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/40240
Related ResourcesLink to Article in PubMed